clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01212822 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P582 | end time | 2014-10-24 | |
P1050 | medical condition | adenocarcinoma | Q356033 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 20 | |
P4844 | research intervention | fluorouracil | Q238512 |
calcium oxalate | Q412399 | ||
bevacizumab | Q413299 | ||
leucovorin calcium | Q27077063 | ||
immunological antineoplastic agent | Q50429626 | ||
P6153 | research site | Case Western Reserve University | Q1047060 |
Fox Chase Cancer Center | Q5476635 | ||
P580 | start time | 2011-04-27 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer |
Search more.